Currently clinical trials are underway involving c-MET and cancers including NSCLC, hepatocellular carcinoma, renal cell carcinoma, cholangiocarcinoma, triple negative breast adenocarcinoma, gastric or esophageal adenocarcinoma, and anaplastic large cell lymphoma, to name a few (http://clinicaltrials.gov/ct2/results?term=met). This evidence concerns the gene MET and esophageal adenocarcinoma.